JP6655014B2 - ウイルスベクター産生系 - Google Patents

ウイルスベクター産生系 Download PDF

Info

Publication number
JP6655014B2
JP6655014B2 JP2016541089A JP2016541089A JP6655014B2 JP 6655014 B2 JP6655014 B2 JP 6655014B2 JP 2016541089 A JP2016541089 A JP 2016541089A JP 2016541089 A JP2016541089 A JP 2016541089A JP 6655014 B2 JP6655014 B2 JP 6655014B2
Authority
JP
Japan
Prior art keywords
vector
expression
trap
virus
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016541089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500870A (ja
Inventor
ファーリー,ダニエル
ミトロファノス,キリアコス
Original Assignee
オックスフォード バイオメディカ(ユーケー)リミテッド
オックスフォード バイオメディカ(ユーケー)リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オックスフォード バイオメディカ(ユーケー)リミテッド, オックスフォード バイオメディカ(ユーケー)リミテッド filed Critical オックスフォード バイオメディカ(ユーケー)リミテッド
Publication of JP2017500870A publication Critical patent/JP2017500870A/ja
Priority to JP2020014654A priority Critical patent/JP7340471B6/ja
Application granted granted Critical
Publication of JP6655014B2 publication Critical patent/JP6655014B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/55—Vectors comprising a special translation-regulating system from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016541089A 2013-12-20 2014-12-19 ウイルスベクター産生系 Active JP6655014B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020014654A JP7340471B6 (ja) 2013-12-20 2020-01-31 ウイルスベクター産生系

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1322798.8A GB201322798D0 (en) 2013-12-20 2013-12-20 Production system
GB1322798.8 2013-12-20
PCT/GB2014/053813 WO2015092440A1 (en) 2013-12-20 2014-12-19 Viral vector production system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020014654A Division JP7340471B6 (ja) 2013-12-20 2020-01-31 ウイルスベクター産生系

Publications (2)

Publication Number Publication Date
JP2017500870A JP2017500870A (ja) 2017-01-12
JP6655014B2 true JP6655014B2 (ja) 2020-02-26

Family

ID=50071322

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016541089A Active JP6655014B2 (ja) 2013-12-20 2014-12-19 ウイルスベクター産生系
JP2020014654A Active JP7340471B6 (ja) 2013-12-20 2020-01-31 ウイルスベクター産生系
JP2022064011A Pending JP2022091989A (ja) 2013-12-20 2022-04-07 ウイルスベクター産生系

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020014654A Active JP7340471B6 (ja) 2013-12-20 2020-01-31 ウイルスベクター産生系
JP2022064011A Pending JP2022091989A (ja) 2013-12-20 2022-04-07 ウイルスベクター産生系

Country Status (10)

Country Link
US (2) US10544429B2 (cg-RX-API-DMAC10.html)
EP (2) EP3083969B1 (cg-RX-API-DMAC10.html)
JP (3) JP6655014B2 (cg-RX-API-DMAC10.html)
KR (1) KR102354365B1 (cg-RX-API-DMAC10.html)
CN (1) CN106029891B (cg-RX-API-DMAC10.html)
DK (1) DK3083969T3 (cg-RX-API-DMAC10.html)
ES (2) ES2748377T3 (cg-RX-API-DMAC10.html)
GB (1) GB201322798D0 (cg-RX-API-DMAC10.html)
PL (1) PL3083969T3 (cg-RX-API-DMAC10.html)
WO (1) WO2015092440A1 (cg-RX-API-DMAC10.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
CN107708710A (zh) 2015-03-17 2018-02-16 嵌合体生物工程公司 Smart CAR装置,DE CAR多肽,Side CAR及其使用
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN109069668B (zh) 2015-12-14 2023-04-18 宾夕法尼亚州大学信托人 用于眼病的基因疗法
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10222369B2 (en) 2016-05-17 2019-03-05 Chimera Bioengineering, Inc. Methods for making novel antigen binding domains
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3831281B1 (en) 2016-08-30 2026-02-25 The Regents of The University of California Devices and systems for biomedical targeting and delivery
CN110121352B (zh) * 2016-09-01 2020-12-11 嵌合体生物工程公司 Gold优化的car t-细胞
EP3519569B1 (en) * 2016-09-30 2020-12-02 Esteve Pharmaceuticals, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
US11783918B2 (en) 2016-11-30 2023-10-10 Microsoft Technology Licensing, Llc DNA random access storage system via ligation
US10793897B2 (en) * 2017-02-08 2020-10-06 Microsoft Technology Licensing, Llc Primer and payload design for retrieval of stored polynucleotides
CN110650624A (zh) * 2017-03-10 2020-01-03 威斯康星州医药大学股份有限公司 用于视网膜疾病的核糖开关调节的基因治疗
EP3595705A1 (en) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Method
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CA3099990A1 (en) * 2017-05-12 2018-11-15 University Of Massachusetts Viral vector production
US11827898B2 (en) 2017-06-14 2023-11-28 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
CA3077594C (en) 2017-10-10 2022-11-29 Nantbio, Inc. Modified ec7 cells having low toxicity to viral production payloads
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
FI3633040T3 (fi) 2017-12-22 2023-08-03 Oxford Biomedica Ltd Retrovirusvektori
EP3806870A4 (en) 2018-02-13 2021-12-22 Chimera Bioengineering, Inc. COORDINATION OF GENE EXPRESSION USING RNA DESSTABILIZATION ELEMENTS
BR112020020204A2 (pt) * 2018-04-05 2021-01-19 Oxford University Innovation Limited Composições e métodos para tratamento da distrofia macular
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
GB201807945D0 (en) * 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
WO2020047476A1 (en) * 2018-08-31 2020-03-05 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN113423419A (zh) 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
EP3906311A4 (en) * 2019-01-06 2022-09-28 Abintus Bio, Inc. CAR-T CELL METHODS AND CONSTRUCTS
CN113454105A (zh) * 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
EP4004204A1 (en) * 2019-07-23 2022-06-01 Oxford BioMedica (UK) Limited Enhancing production of lentiviral vectors
US20210046117A1 (en) 2019-08-18 2021-02-18 Chimera Bioengineering, Inc. Combination Therapy with Gold Controlled Transgenes
KR20210026024A (ko) 2019-08-29 2021-03-10 변정원 학습에 대한 보상을 제공하여 동기부여를 높이는 학습 보조 어플리케이션
CA3151982A1 (en) * 2019-10-16 2021-04-22 Stephen H. Thorne Producer viruses for generation of retroviruses in situ
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
US20240052366A1 (en) * 2020-02-13 2024-02-15 Oxford Biomedica (Uk) Limited Production of Lentiviral Vectors
KR20220153021A (ko) * 2020-03-11 2022-11-17 리모터 테라퓨틱스, 인코포레이티드 중추신경계를 통한 단백질을 확산시키기 위한 방법 및 재료
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
CN113699112A (zh) * 2020-05-20 2021-11-26 苏州方德门达新药开发有限公司 表达重组hsv-1 us11蛋白的工程细胞及其在提高慢病毒包装效率中的应用
EP4158039A4 (en) * 2020-05-26 2024-11-13 Transcytos, LLC DEVICES AND METHODS FOR TRANSFECTION
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
CN112430582B (zh) * 2020-12-04 2022-05-03 北京艺妙神州医药科技有限公司 一种慢病毒稳定包装细胞系及其制备方法
CN112501210B (zh) * 2020-12-07 2022-08-05 和元生物技术(上海)股份有限公司 外源基因可控表达的慢病毒包装方法
GB202102832D0 (en) * 2021-02-26 2021-04-14 Ip2Ipo Innovations Ltd Retroviral vectors
EP4408894A4 (en) 2021-09-29 2025-08-20 Chimera Bioengineering Inc Compositions and methods for anti-tnmuc1 gold car t-cells
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
CN114181972A (zh) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
CN114107231B (zh) * 2021-12-13 2023-08-18 重庆大学 实现全脑突触后神经元胞体标记的重组腺相关病毒及其应用
CN114639442B (zh) * 2022-03-30 2024-01-30 中国农业科学院农业基因组研究所 一种基于单核苷酸多态性预测开放阅读框的方法及系统
EP4507719A1 (en) 2022-04-13 2025-02-19 Universitat Autònoma de Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
CN115161345A (zh) * 2022-06-14 2022-10-11 同宜医药(苏州)有限公司 高表达FRα的重组载体、重组细胞及其构建方法和用途
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
EP4601659A2 (en) * 2022-10-12 2025-08-20 University of Kansas Third-generation lentiviral gene therapy rescues function in a mouse model of usher ib
WO2024151704A2 (en) * 2023-01-10 2024-07-18 Sana Biotechnology, Inc. Process for viral vector production
CN116621947B (zh) * 2023-07-18 2023-11-07 北京智源人工智能研究院 一种基于索烃骨架的拓扑蛋白质、制备方法及应用
WO2025153852A1 (en) * 2024-01-17 2025-07-24 1. Revvity Gene Delivery Gmbh Production of viral vectors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1996009385A1 (en) 1994-09-19 1996-03-28 Massachusetts Institute Of Technology Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CZ297278B6 (cs) 1996-08-07 2006-10-11 Darwin Discovery Limited Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
WO1999032646A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
AU4924199A (en) * 1998-07-30 2000-02-21 Advec, Inc. Repressor proteins producing cell lines for the propagation of vectors
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
DK2348119T3 (en) 2002-02-01 2017-08-21 Oxford Biomedica (Uk) Ltd Polycistronic lentiviral vector
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
GB0526210D0 (en) * 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
US8841438B2 (en) * 2009-05-22 2014-09-23 The Research Foundation Of The University Of New York Trans-acting RNA switches
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
WO2014043131A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of California Lentiviral vector for stem cell gene therapy of sickle cell disease

Also Published As

Publication number Publication date
KR20160122125A (ko) 2016-10-21
EP3650548B1 (en) 2022-03-09
GB201322798D0 (en) 2014-02-05
WO2015092440A1 (en) 2015-06-25
US10544429B2 (en) 2020-01-28
PL3083969T3 (pl) 2020-03-31
US20200102578A1 (en) 2020-04-02
JP2020096609A (ja) 2020-06-25
JP7340471B6 (ja) 2024-02-26
EP3083969B1 (en) 2019-08-07
JP7340471B2 (ja) 2023-09-07
KR102354365B1 (ko) 2022-01-20
ES2748377T3 (es) 2020-03-16
EP3650548A1 (en) 2020-05-13
US12054735B2 (en) 2024-08-06
US20160333373A1 (en) 2016-11-17
CN106029891A (zh) 2016-10-12
JP2017500870A (ja) 2017-01-12
CN106029891B (zh) 2021-09-07
DK3083969T3 (da) 2019-10-14
EP3083969A1 (en) 2016-10-26
ES2911805T3 (es) 2022-05-20
JP2022091989A (ja) 2022-06-21

Similar Documents

Publication Publication Date Title
JP7340471B2 (ja) ウイルスベクター産生系
ES2951857T3 (es) Vector retroviral
JP7759318B2 (ja) 産生系
JP7787064B2 (ja) レンチウイルスベクターの製造の増強
US20240052366A1 (en) Production of Lentiviral Vectors
US20230118587A1 (en) Lentiviral Vectors
EP4305165A1 (en) Lentivirus with altered integrase activity
WO2023062359A2 (en) Novel viral regulatory elements
WO2023062365A2 (en) Lentiviral vectors
US20230183742A1 (en) Viral Vector Production

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200131

R150 Certificate of patent or registration of utility model

Ref document number: 6655014

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250